drugset
drugset / Trial / NCT04920578

A Study of JNJ-69095897 in Healthy Participants

NCT04920578 ↗

Phase 1 Terminated 48 enrolled Janssen Research & Development, LLC
RandomizedSequentialDouble-blindOther

Summary

The purpose of this study is to investigate the safety and tolerability of JNJ-69095897 versus placebo and to characterize the pharmacokinetic (PK) of JNJ-69095897 in blood, plasma, cerebrospinal fluid (CSF) and urine after single or divided oral dose administration in healthy participants.

Timeline

Start
2021-06-16
Primary completion
2023-01-27
Completion
2023-02-27

Outcome

Outcome not reported

Stopped (Business): “business decision to end clinical development of JNJ-69095897”

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-69095897 Unknown — Oral

Indications

No indication recorded.